myasthenia gravis

Top Most Expensive Drugs in the US Healthcare Market
Top 12 Most Expensive Drugs in the US Healthcare Market

Drug pricing is one of the hottest topics in the healthcare segment. Several arguments have been put forward by people, governments, healthcare companies, and other organizations in favor of and a...


Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa
Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZenec...

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B ...


pharma-news-for-biogen-sanofi-bristol-pharming-ucb-eli-lilly
Biogen’s Aduhelm; FDA Approves Sanofi’s Enjaymo; NHS & Orchard Signs a Deal; Bri...

Biogen's Aduhelm Marketing and Approval are Under Scrutiny in New FTC and SEC Investigations Biogen can't seem to get a break when it comes to the Alzheimer's disease drug Aduhelm. Along with l...


upcoming-drugs-for-autoimmune-diseases
Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases

The autoimmune diseases are frequently incapacitating and, in some circumstances, fatal. There are currently more than 80 identified autoimmune disorders, such as Rheumatoid Arthritis, Crohn's Dis...


myasthenia-gravis-treatment-market-growth-size-therapies-forecast-and-key-companies
Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It occurs when the communication between nerve cells and muscles is disrupted. This impairment prevents critical...


pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $...

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had...


Pharma news
Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma...

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50 joint venture w...


Myasthenia gravis market
Myasthenia gravis Market Outlook

Myasthenia gravis (MG) is an autoimmune syndrome that causes weakness in the skeletal muscles caused due to the failure of neuromuscular transmission. Communication between nerve cells and muscles...


Myasthenia Gravis
Myasthenia Gravis Awareness Month

Myasthenia Gravis June is Myasthenia Gravis Awareness Month. Myasthenia gravis is a disorder causing weakness and easy fatigue of voluntary muscles. It is caused by a breakdown in the communi...


Myasthenia gravis (MG)
Myasthenia Gravis

https://www.slideshare.net/DelveInsight/myasthenia-gravis-126250701?qid=b9adbccf-6d91-4e5e-84e1-7603c87a029e&v=&b=&from_search=1 Myasthenia gravis (MG) is an autoimmune syndrome caus...


Editor's Pick
Can denovoSkin Be A Lifesaver for Burn Victims?

Burn is a global public health problem, causing more than 180,000 deaths per year acros...

NexoBrid and its Awaiting US Approval

A Burn takes place when the skin comes into contact with a heat source. Burns can occur...

New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Do...

Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...

Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.